Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients

被引：56

作者：

Cicenas, J

Urban, P

Küng, W

Vuaroqueaux, V

Labuhn, M

Wight, E

Eppenberger, U

Eppenberger-Castori, S

机构：

[1] Stiftung Tumorbank Basel, CH-4125 Riehen, Switzerland

[2] OncoScore AG, Riehen, Switzerland

[3] Univ Basel, Dept Res, Basel, Switzerland

[4] Univ Clin, Kantonsspital Basel, Basel, Switzerland

来源：

EUROPEAN JOURNAL OF CANCER | 2006年 / 42卷 / 05期

关键词：

phosphorylation; ERBB2 (HER2/Neu); immunoassay; biomarker; prognosis; breast cancer;

D O I：

10.1016/j.ejca.2005.11.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ERBB2 (HER2/Neu) gene amplification and overexpression is associated with increased risk of metastases and shorter survival in breast cancer. Tyrosine 1248 is a major phosphorylation site of ERBB2 and reflects the activation status of the receptor. The aim of this study was to investigate the relationships between quantitative levels of pY1248-ERBB2 (p-ERBB2) and the expression of epidermal growth factor receptor (EGFR)-family members, and whether p-ERBB2 could provide additional prognostic value compared with established prognostic markers. For this purpose we developed a highly sensitive chemiluminescence-linked immunoassay (CLISA) and detected p-ERBB2 levels in 70 primary breast cancer biopsies. Phosphorylated ERBB2 correlated with EGFR and ERBB2, and inversely with oestrogen receptor (ER), progesterone receptor (PgR) and ERBB4 expression levels. Additionally, p-ERBB2 was associated with poor clinical outcome in univariate and multivariate Cox regression analysis. Further studies are needed to evaluate the predictive value of p-ERBB2. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：636 / 645

页数：10

共 26 条

[1] Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer [J].

Agus, DB ;

Gordon, MS ;

Taylor, C ;

Natale, RB ;

Karlan, B ;

Mendelson, DS ;

Press, MF ;

Allison, DE ;

Sliwkowski, MX ;

Lieberman, G ;

Kelsey, SM ;

Fyfe, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2534-2543

[2]

[Anonymous], 1984, CLASSIFICATION REGRE

[3] MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].

BARGMANN, CI ;

HUNG, MC ;

WEINBERG, RA .

CELL, 1986, 45 (05) :649-657

[4] c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells [J].

Brandt, BH ;

Roetger, A ;

Dittmar, T ;

Nikolai, G ;

Seeling, M ;

Merschjann, A ;

Nofer, JR ;

Dehmer-Möller, G ;

Junker, R ;

Assmann, G ;

Zaenker, KS .

FASEB JOURNAL, 1999, 13 (14) :1939-1949

[5]

COSTA S, 1988, LANCET, V2, P1258

[6] A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer [J].

De Laurentiis, M ;

Arpino, G ;

Massarelli, E ;

Ruggiero, A ;

Carlomagno, C ;

Ciardiello, F ;

Tortora, G ;

D'Agostino, D ;

Caputo, F ;

Cancello, G ;

Montagna, E ;

Malorni, L ;

Zinno, L ;

Lauria, R ;

Bianco, AR ;

De Placido, S .

CLINICAL CANCER RESEARCH, 2005, 11 (13) :4741-4748

[7]

DIGIOVANNA MP, 1995, CANCER RES, V55, P1946

[8]

DiGiovanna MP, 2002, CANCER RES, V62, P6667

[9] Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via epidermal growth factor receptor [J].

Dittmar, T ;

Husemann, A ;

Schewe, Y ;

Nofer, JR ;

Niggemann, B ;

Zänker, KS ;

Brandt, BH .

FASEB JOURNAL, 2002, 16 (11) :1823-+

[10] Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay [J].

Eppenberger-Castori, S ;

Kueng, W ;

Benz, C ;

Caduff, R ;

Varga, Z ;

Bannwart, F ;

Fink, D ;

Dietrich, H ;

Hohl, M ;

Müller, H ;

Paris, K ;

Schoumacher, F ;

Eppenberger, U .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :645-656

← 1 2 3 →